Loading...
•
Nov 30, 2022
Nurix Q4 2022 Earnings Report
Reported financial results for the fourth quarter and fiscal year ended November 30, 2022 and provided a corporate update.
Key Takeaways
Nurix Therapeutics reported collaboration revenue of $6.8 million for the quarter and a net loss of $46.7 million, or ($0.87) per share. The company's cash, cash equivalents and marketable securities totaled $373.0 million as of November 30, 2022.
NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies
Achieved significant milestones in wholly owned clinical programs and partnered preclinical programs
Maintained strong financial position with year-end cash and marketable securities totaling $373 million
Presented multiple posters highlighting data from Nurix’s Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nurix
Nurix
Nurix Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Nurix anticipates presenting additional clinical results for NX-2127 in the second half of 2023 and defining a regulatory strategy based on emerging clinical data and FDA feedback. Initial clinical data from the Phase 1a portion of the NX-5948 study is expected in the second half of 2023, with a dose defined for Phase 1b cohort expansion. Clinical data from the Phase 1a portion of the NX-1607 study is expected in the second half of 2023, with a dose defined for Phase 1b cohort expansion. Nurix expects to select a new targeted protein degrader development candidate in 2023 and continue to achieve substantial research collaboration milestones throughout 2023 with Gilead Sciences and Sanofi.
Positive Outlook
- Presenting additional clinical results for NX-2127 in the second half of 2023.
- Defining a regulatory strategy for NX-2127 in the second half of 2023.
- Presenting initial clinical data from the Phase 1a portion of the NX-5948 study in the second half of 2023.
- Defining a dose for Phase 1b cohort expansion for NX-5948.
- Presenting clinical data from the Phase 1a portion of the NX-1607 study in the second half of 2023.
Challenges Ahead
- No specific negative guidance mentioned in the provided text.